Medication Profile · Updated March 2026

Wegovy (Semaglutide 2.4mg): Cost, Weight Loss Data, and How to Get It in 2026

Wegovy is semaglutide built specifically for weight loss. Same molecule as Ozempic, but at a higher dose and with an FDA approval that actually says "chronic weight management" on the label. It is also the only GLP-1 with proven cardiovascular benefits in non-diabetic patients. And as of 2025, there is an oral pill version. Here is the full picture for anyone considering Wegovy in 2026.

Quick Facts

How Wegovy Works

Wegovy is a GLP-1 receptor agonist. It mimics a naturally occurring hormone called glucagon-like peptide-1 that plays a role in appetite regulation and blood sugar control. The mechanism is the same as Ozempic (they are literally the same molecule), but Wegovy is dosed higher and approved for a different purpose.

Here is what semaglutide does in your body:

1. Suppresses appetite. It acts on GLP-1 receptors in the hypothalamus, the part of your brain that regulates hunger. You feel full faster and experience fewer food cravings between meals.
2. Slows digestion. Food moves through your stomach more slowly, which keeps you satisfied longer after eating and reduces post-meal blood sugar spikes.
3. Improves insulin sensitivity. Your body handles blood sugar more efficiently, which is why semaglutide was originally developed for diabetes.
4. Cardiovascular protection. This is unique to Wegovy among GLP-1s. The SELECT trial demonstrated a 20% reduction in major adverse cardiovascular events (heart attack, stroke, cardiovascular death) in overweight or obese patients with existing cardiovascular disease. No other GLP-1 weight loss drug has this data.

The cardiovascular benefit is a big deal. It is the reason Wegovy has an additional FDA-approved indication for reducing cardiovascular risk in adults with established cardiovascular disease and obesity or overweight. This also gives it a significant advantage in insurance coverage discussions, which I will cover below.

For a breakdown of how single-action GLP-1s (like semaglutide) compare to dual-action drugs (like tirzepatide in Mounjaro), see our Mounjaro vs Ozempic comparison.

Dosing Schedule

Wegovy uses a gradual dose escalation to minimize GI side effects. You start low and work up to the maintenance dose over about 16 to 20 weeks.

Injectable Wegovy

The 1.7 mg and 2.4 mg doses are what separate Wegovy from Ozempic. Ozempic maxes out at 2 mg. These higher dose levels were specifically designed for weight management and are where the strongest weight loss data comes from.

Oral Wegovy (Pill)

In 2025, the FDA approved an oral formulation of semaglutide for weight management. This is a daily pill rather than a weekly injection. It is the same active ingredient, absorbed through the stomach lining.

The oral version requires specific timing: take it on an empty stomach with no more than 4 ounces of plain water, then wait at least 30 minutes before eating, drinking, or taking other medications. This is because oral semaglutide is sensitive to stomach acid and food, which can reduce absorption.

For a detailed comparison of the pill and injection, including absorption differences and real-world considerations, read our Wegovy pill vs injection guide.

Weight Loss Results

Wegovy has the most weight loss clinical trial data of any GLP-1 medication. Here are the key numbers.

STEP 1 Trial (the headline study)

Published in the New England Journal of Medicine (2021). Studied semaglutide 2.4 mg in adults with obesity (BMI 30+) or overweight (BMI 27+) with at least one weight-related condition. No diabetes.

Results at 68 weeks:

• Semaglutide 2.4 mg: 14.9% body weight loss (average)
• Placebo: 2.4% body weight loss
• Over one-third of participants lost more than 20% of their body weight
• 86.4% of semaglutide participants lost at least 5% of body weight

What that looks like in practice: For a 220 lb person, 14.9% equals roughly 33 lbs over about 16 months. The top responders in the trial lost considerably more.

STEP 2 (patients with type 2 diabetes)

Weight loss was lower in diabetic patients: 9.6% at 68 weeks. This is a consistent finding across GLP-1 trials. People with diabetes tend to lose less weight on these medications compared to non-diabetic patients.

STEP 3 (with intensive behavioral therapy)

When combined with intensive behavioral therapy (dietary counseling, exercise coaching, calorie restriction), weight loss increased to 16% at 68 weeks. This suggests that medication plus structured lifestyle support outperforms medication alone.

STEP 5 (long-term, 2 years)

Participants maintained 15.2% body weight loss at 104 weeks (2 years), demonstrating that the effect persists with continued use.

SELECT Trial (cardiovascular outcomes)

This is the trial that changed Wegovy’s position in the market. Published in 2023, SELECT studied semaglutide 2.4 mg in over 17,600 adults with obesity or overweight who had established cardiovascular disease but did not have diabetes.

Key findings:

• 20% reduction in the composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke
• This benefit was observed regardless of the amount of weight lost
• First GLP-1 to demonstrate cardiovascular risk reduction in a non-diabetic population

The SELECT data gave Wegovy an additional FDA indication for cardiovascular risk reduction and significantly improved insurance coverage. Insurers who previously refused to cover weight loss medications started approving Wegovy for patients with cardiovascular risk factors, because the trial demonstrated it prevents heart attacks and strokes.

How does this compare to other GLP-1s?

Wegovy’s 14.9% average weight loss is strong, but tirzepatide (Mounjaro/Zepbound) showed even more in the SURMOUNT-1 trial: 22.5% at the highest dose. The tradeoff is that Wegovy has the cardiovascular data and the oral pill option, while tirzepatide does not yet have either. See our full comparison for the complete breakdown.

From tracking my own body composition on Mounjaro with DEXA scans, I have learned that the total weight loss number only tells part of the story. How much of that loss is fat vs. muscle matters enormously for long-term health. Our fat loss vs weight loss guide and exercise guide cover this in depth.

What Wegovy Costs in 2026

Wegovy is the most expensive semaglutide option at list price, but the total cost varies wildly depending on your insurance, eligibility for savings programs, and whether you consider compounded alternatives.

Brand-Name Wegovy

The list price is approximately $1,349 per month without insurance. This is the sticker price at a retail pharmacy with no coverage or discounts applied.

Novo Nordisk savings programs: Through NovoCare, patients with commercial insurance may qualify for a savings card that reduces copays to as low as $0 for certain plans. Introductory pricing for starter doses has been available at $199/month through NovoCare Pharmacy directly.

With insurance: Wegovy has better insurance coverage than most GLP-1 weight loss medications, largely because of the SELECT trial cardiovascular data. Many commercial insurers now cover Wegovy for patients with BMI 30+ (or BMI 27+ with a weight-related condition). Typical copays with coverage range from $0 to $100 per month. Medicare coverage expanded in 2025 for patients with cardiovascular disease indications. Our GLP-1 insurance coverage guide and Medicare coverage guide detail how to get approved.

Compounded Semaglutide

Compounded semaglutide (the same active ingredient at a lower price point) runs $149 to $299 per month through telehealth providers. This is not specifically “compounded Wegovy” since Wegovy is a brand name, but compounded semaglutide at equivalent doses achieves the same pharmacological effect.

The important caveat: compounded semaglutide has not undergone FDA review as a finished product. The active ingredient is the same, but the manufacturing, quality control, and formulation come from compounding pharmacies rather than Novo Nordisk. Read our compounded vs brand-name guide for the full breakdown of risks and tradeoffs.

Cost Comparison Summary

For a complete breakdown of every pricing path, see our cheapest GLP-1 online guide and GLP-1 without insurance guide.

Where to Get Semaglutide Online

If you want brand-name Wegovy, you will generally need a prescription from your doctor and a pharmacy that has it in stock (shortages have been an ongoing issue). For compounded semaglutide at equivalent doses, these are the top-rated telehealth providers by ClearScore.

For the complete provider directory with filtering by state, medication type, and price, visit our provider comparison page.

Common Side Effects

Wegovy’s side effect profile is the same as Ozempic’s, because it is the same drug. The frequency and intensity can differ at higher doses (especially 1.7 mg and 2.4 mg), where GI symptoms tend to be more pronounced.

Most common (reported by 10% or more of participants in STEP trials):

• Nausea (44% of participants at some point, mostly in early weeks and dose increases)
• Diarrhea (30%)
• Vomiting (24%)
• Constipation (24%)
• Abdominal pain (20%)

Less common but notable:

• Headache
• Fatigue
• Dizziness
• Injection site reactions
• Acid reflux (GERD)

Serious but rare:

• Pancreatitis (severe abdominal pain that does not go away warrants immediate medical attention)
• Gallbladder problems and gallstones
• Kidney injury, typically secondary to dehydration from vomiting/diarrhea
• Increased heart rate (a small but consistent finding in trials, typically 2 to 4 beats per minute)

Boxed warning: Like all semaglutide products, Wegovy carries a boxed warning about thyroid C-cell tumors found in animal studies. Not confirmed in humans, but the medication is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).

Managing side effects: The dose escalation schedule exists specifically to reduce GI side effects. Most nausea and digestive issues improve over the first 4 to 8 weeks at each dose level. Eating smaller meals, staying hydrated, and avoiding high-fat foods all help. For a month-by-month timeline of what to expect (and what actually worked for me on Mounjaro), see our GLP-1 side effects guide.

Wegovy vs. Related Medications

Wegovy vs. Ozempic: Same molecule (semaglutide), same manufacturer (Novo Nordisk). Ozempic is approved for type 2 diabetes with doses up to 2 mg. Wegovy is approved for weight management with doses up to 2.4 mg. If your primary goal is weight loss, Wegovy is the version that was designed and tested for that purpose. Full Ozempic profile.

Wegovy vs. Zepbound: This is the real comparison that matters in 2026. Zepbound (tirzepatide) works on two receptors (GIP + GLP-1) vs. Wegovy’s one (GLP-1 only). Zepbound shows higher weight loss in trials (roughly 22.5% vs. 14.9%). But Wegovy has the cardiovascular outcome data from SELECT, the oral pill option, and generally better insurance coverage. Your best option depends on your specific health profile and insurance situation. Full comparison.

Wegovy vs. Compounded Semaglutide: Brand-name Wegovy costs around $1,349/month without insurance. Compounded semaglutide costs $149 to $299/month. The active ingredient is the same, but compounded products have not been through FDA review as finished medications. Compounded vs brand-name guide.

Wegovy Pill vs. Wegovy Injection: The oral pill approved in 2025 offers a needle-free option. Absorption and bioavailability differ from the injectable form, and the pill requires specific timing around meals. We cover the full comparison in our Wegovy pill vs injection guide. For a broader look at oral vs. injectable GLP-1s, see our oral vs injectable guide.

Frequently Asked Questions

Related Resources

• Mounjaro vs Ozempic vs Wegovy vs Zepbound (2026)
• Wegovy Pill vs Injection: Which One to Choose
• Oral vs Injectable GLP-1 Medications
• Cheapest Way to Get GLP-1 Medications Online
• GLP-1 Side Effects: Month by Month Guide
• GLP-1 Insurance Coverage Guide
• GLP-1 Medicare Coverage in 2026
• Compounded vs Brand-Name GLP-1